Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies

被引：53
|
作者：
Lejeune, Julien [1 ]
Thibault, Gilles [2 ,3 ]
Ternant, David [1 ]
Cartron, Guillaume [4 ,5 ]
Watier, Herve [2 ]
Ohresser, Marc [1 ]
机构：
[1] Univ Tours, CNRS, Unite Mixte Rech 6239, Tours, France
[2] Ctr Hosp Reg Univ Tours, Immunol Lab, Tours, France
[3] Univ Auvergne Clermont 1, Clermont Ferrand, France
[4] INSERM, U847, Montpellier, France
[5] Ctr Hosp Univ Lapeyronie, Serv Hematol & Biotherapies, Montpellier, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 33期
关键词：
D O I：
10.1200/JCO.2008.19.4118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5489 / 5491
页数：4
相关论文
共 9 条
  • [1] Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies IN REPLY
    Musolino, Antonino
    Naldi, Nadia
    Bortesi, Beatrice
    Pezzuolo, Debora
    Capelletti, Marzia
    Missale, Gabriele
    Laccabue, Diletta
    Zerbini, Alessandro
    Camisa, Roberta
    Bisagni, Giancarlo
    Neri, Tauro Maria
    Ardizzoni, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5491 - 5492
  • [2] Polymorphisms of FcγRIIA, FcγRIIB, and FcγRIIIA and Therapeutic Response to Rituximab Combination Therapy in Patients with Waldenstrom's Macroglobulinemia
    Yang, Guang
    Hanzis, Christina
    Gong, Ping
    Verselis, Sigitas
    Fox, Edward A.
    Xu, Lian
    Ciccarelli, Bryan
    Zhou, Yangsheng
    Hunter, Zachary
    Sun, Jenny
    Liu, Xia
    Tseng, Hsiuyi
    Cao, Yang
    Manning, Robert
    Lewicki, Megan
    Ioakimidis, Thea
    Sheehy, Patricia
    Patterson, Christopher J.
    Treon, Steven
    BLOOD, 2009, 114 (22) : 1152 - 1153
  • [3] Distributions of FcγRIIa-131 and FcγRIIIa-158 polymorphisms and clinical response to cetuximab in Japanese patients with metastatic colorectal cancer (mCRC)
    Fukushima, H.
    Yoshino, T.
    Yamazaki, K.
    Nishina, T.
    Yuki, S.
    Kadowaki, S.
    Shinozaki, E.
    Yokota, T.
    Kajiura, S.
    Yamanaka, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [4] Fc gamma RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gamma RIIIa, independently of the Fc gamma IIIa-48L/R/H phenotype
    Koene, HR
    Kleijer, M
    Algra, J
    Roos, D
    vondemBorne, AEGK
    deHaas, M
    BLOOD, 1997, 90 (03) : 1109 - 1114
  • [5] Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients
    Schiele, Phillip
    Kolling, Stefan
    Rosnev, Stanislav
    Junkuhn, Charlotte
    Walter, Anna Luzie
    von Einem, Jobst Christian
    Stintzing, Sebastian
    Schoening, Wenzel
    Sauer, Igor Maximilian
    Modest, Dominik Paul
    Heinrich, Kathrin
    Weiss, Lena
    Heinemann, Volker
    Bullinger, Lars
    Frentsch, Marco
    Na, Il-Kang
    CELLS, 2025, 14 (01)
  • [6] Investigation of FcγR Polymorphisms and response to IL-2 (Proleukin®) and rituximab treatment in rituximab-resistant NHL patients:: Importance of the F/F polymorphism at position 158 of the FcγRIIIa.
    Emmanouilides, C
    Khan, KD
    Piro, L
    Michelson, G
    Giordano, H
    Milan, S
    Wilson, SE
    Eisenbeis, C
    Caligiuria, M
    BLOOD, 2004, 104 (11) : 239B - 239B
  • [7] FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma
    Fabisiewicz, Anna
    Paszkiewicz-Kozik, Ewa
    Osowiecki, Michal
    Walewski, Jan
    Siedlecki, Janusz A.
    LEUKEMIA & LYMPHOMA, 2011, 52 (08) : 1604 - 1606
  • [8] The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects
    Oboshi, Wataru
    Watanabe, Toru
    Matsuyama, Yuumi
    Kobara, Ayana
    Yukimasa, Nobuyasu
    Ueno, Ichiro
    Aki, Kensaku
    Tada, Tomoki
    Hosoi, Eiji
    HUMAN IMMUNOLOGY, 2016, 77 (02) : 165 - 171
  • [9] Correlation of FcγR IIa-H131R and IIIa-V158F polymorphisms and clinical outcome of trastuzumab in both neoadjuvant and metastatic setting in patients with HER-2 positive breast cancer
    Tamura, K.
    Shimizu, C.
    Koizumi, F.
    Kouno, T.
    Katsumata, N.
    Kinoshita, T.
    Aogi, K.
    Nishio, K.
    Ando, M.
    Fujiwara, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
1